SmartHeart SIGNED
SmartHeart, a 3D in vitro assay for improved assessment of cardiac drug efficacy and toxicity
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0SmartHeart project word cloud
Explore the words cloud of the SmartHeart project. It provides you a very rough idea of what is the project "SmartHeart" about.
Project "SmartHeart" data sheet
The following table provides information about the project.
| Coordinator |
4DCELL
Organization address contact info |
| Coordinator Country | France [FR] |
| Total cost | 196˙707 € |
| EC max contribution | 196˙707 € (100%) |
| Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
| Code Call | H2020-MSCA-IF-2019 |
| Funding Scheme | MSCA-IF-EF-SE |
| Starting year | 2020 |
| Duration (year-month-day) | from 2020-03-02 to 2022-03-01 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | 4DCELL | FR (MONTREUIL) | coordinator | 196˙707.00 |
Map
Project objective
Currently, animal models are still widely used in the pre-clinical stage of drug development to mimic human diseases or predict the human body’s response to candidate drugs. However, their use should be minimized as much as possible due to ethical issues and since only 9.6% of drugs entering phase I of clinical trials end up being commercialized. Therefore, the goal of this action is to develop a novel proprietary 3D in vitro cardiac assay. The SmartHeart will retrieve several of the most important read-outs commonly assessed to study the impact of drugs at the cardiac level in the pre-clinical phase. The all in one assay will be based on a microstructured gel where cardiac cells, as cardiomyocytes derived from induced pluripotent stem cells will be cultured. The SmartHeart will answer to the shortcomings of academic and commercial available in vitro assays, by enabling the qualitative and quantitative measurement of several parameters, as contractility and Calcium transients. Simultaneously, the assay will enable sub-cellular structure observation via high-resolution imaging techniques. Furthermore, the 3D nature of the assay will contribute to the efficient maturation of the induced CMs, which is still a limiting factor when not using cardiac human cells, but rather induced CMs, in in vitro assays. The ultimate aim of the project is to make this device available to screening platforms, e.g. Pharma or CROs. The technology will be implemented in multiwell plates compatible with the standards of HTS/HCS and will be available to early-users, from whom feedback will be acquired, enabling to fine tune the specifications of the final device. This project will meet the best of the ER competences in physics, with the expertise of 4Dcell in 3Dcell culture systems. With this project, the ER will reach a level of maturity on several technological, managerial and industrial aspects providing her a new career angle and put her a step closer to act as a leader in research.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SMARTHEART" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SMARTHEART" are provided by the European Opendata Portal: CORDIS opendata.
More projects from the same programme (H2020-EU.1.3.2.)
RipGEESE (2020)
Identifying the ripples of gene regulation evolution in the evolution of gene sequences to determine when animal nervous systems evolved
Read More